cancer-therapy-and-biomarkers-2016_tracks-abstracts

17 / 36

Volume 2, Issue 3(Suppl) Oncol Cancer Case Rep
ISSN: 2471-8556 an open access journal
Page 44
Notes:
Cancer Therapy & Biomarkers 2016
December 05-07, 2016
conferenceseries.com
CANCER THERAPY,
BIOMARKERS & CLINICAL RESEARCH
15th World Congress on
December 05-07, 2016 Philadelphia, USA
Inhibitive effect of Non-viable derivatives of Clostridium sporogenes on colorectal cancer cells
Madhura Satish Bhave
Nanyang Technological University, Singapore
Traditional cancer treatments like chemotherapy and radiation therapy continue to have limited efficacy due to phenomena
like tumor hypoxia and multi-drug resistance. Bacterial cancer therapy has the potential to overcome these problems,
through the use of anaerobic spores of bacteria such as the proteolytic Clostridium sporogenes. However, the use of spores or
live bacteria comes with the risk of toxicity and infection. To circumvent these issues, the anti-cancer effect of heat-inactivated
C. sporogenes bacteria (IB) and its secreted bacterial proteins, known as Conditioned Media (CM) was investigated. These
non-viable bacterial derivatives were administered to CT26 and HCT116 colorectal cancer cells in a 2-Dimensional (2D) and a
3-Dimensional (3D) platform. IB significantly inhibited cell proliferation of CT26 in a dose-dependent manner to 6.3% of the
control in 72 hours for the 2D monolayer culture. In the 3D spheroid culture, cell proliferation of HCT116 spheroids notably
dropped to 26.2%. Similarly the CM also remarkably reduced the cell-proliferation of the CT26 cells to 2.4% and 20% in the
2D and 3D models, respectively. Results suggest that physical interaction between the IB and the cancer cells lead to their in-
hibition, while the secreted proteins present in CM were responsible for anti-cancer effect observed. The bacterial derivatives
exhibited strong inhibitive effects on colorectal cancer cells, indicating that there is a safer alternative to the use of spores and
live bacteria. With further research, these non-viable derivatives could be developed as an alternative or adjunct to traditional
cancer treatments.
Biography
Madhura is currently pursuing her PhD at Nanyang Technological University (NTU), Singapore. She completed her Bachelor of Engineering in Bioengineering from
NTU where her final year honours thesis was on the subject of Bacterial Cancer Therapy. She was on the Dean’s List for the academic year of 2014/2015. Her work
has been published in the Scientific Reports journal, by the Nature Publishing Group.
Madhura Satish Bhave, Oncol Cancer Case Rep 2016,2:3(Suppl)